The diagnosed population for BRCA1 mutation rate in TNBC breast cancer, including both germline and somatic mutation, is about 15–20%, which means approximately 80% of BRCA1‐proficient TNBC breast cancer patients could not benefit from PARP inhibitors treatment (Hartman et al, 2012; Greenup et al, 2013; Johnson et al, 2016). This evidence concerns the gene PARP1 and breast carcinoma.